(Q43288119)

18 November 2017

title

Safety of double-dose transdermal scopolamine (English)

1 reference

18 November 2017

3

Dror Tal

1 reference

18 November 2017

Ronen Bar

1

1 reference

18 November 2017

Amnon Gil

series ordinal

2

1 reference

18 November 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

18 November 2017

1 reference

18 November 2017

volume

29

1 reference

18 November 2017

issue

9

1 reference

18 November 2017

page(s)

1082-1088

1 reference

Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications

18 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.9.1082

Transdermal hyoscine (Scopolamine). A preliminary review of its pharmacodynamic properties and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.9.1082

Transdermally administered scopolamine vs. dimenhydrinate. I. Effect on nausea and vertigo in experimentally induced motion sickness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.9.1082

A comparison of plasma levels of hyoscine after oral and transdermal administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.9.1082

Simple radioligand binding assay for the determination of urinary scopolamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.9.1082

Transdermal scopolamine use in the control of narcotic-induced nausea

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.9.1082

21 January 2018

Identifiers

DOI

10.1592/PHCO.29.9.1082

1 reference

18 November 2017

1 reference